Novo Nordisk's 3 Million Wegovy Prescriptions and a $2.1 Billion Bet Face a $25 Million Ransomware Reckoning

Despite a 41% stock drop and $25M ransomware attack, Novo Nordisk's oral semaglutide sees 3M+ prescriptions, fueling expansion and partnerships.

The numbers tell a brutal story on the surface. Novo Nordisk's shares have shed roughly 41% over the past year, trading at €37.97 — a far cry from the €65.20 high. Yet beneath the headline collapse, a far more complex picture is emerging. The Danish drugmaker is simultaneously fighting off a $25 million ransomware attack, racing to scale an oral obesity pill that has already racked up more than 3 million prescriptions, and pouring billions into production capacity and new partnerships.

Cybercriminals from the group FulcrumSec claim to have exfiltrated 1.3 terabytes of data, including source code, clinical trial information, employee records, and AI models. The ransom demand: $25 million. Novo Nordisk confirmed the breach on June 11 and acknowledged that pseudonymised study data and physician details were compromised. Analysts suspect the attackers gained access via exposed credentials in development environments. The company insists that day-to-day operations and product deliveries remain unaffected.

That operational confidence rests on a commercial engine that is still firing. The oral formulation of semaglutide — Wegovy in pill form — launched in the US on January 5 and has already been prescribed more than 3 million times in under six months. Over 80% of those patients had never used a GLP-1 therapy before, signalling that Novo Nordisk is expanding the market rather than simply cannibalising its injectable franchise. In Britain, the MHRA approved the 25 mg tablet on June 11, citing OASIS-4 trial data showing a 13.6% weight loss over 64 weeks versus 2.4% for placebo. CEO Mike Doustdar has flagged plans to file for approval in China in the coming months, aiming to get ahead of Eli Lilly's own oral contender.

Away from the pill, the pipeline is being reinforced with high-stakes deals. Novo Nordisk partnered with Boston-based Vivtex in a pact worth up to $2.1 billion, harnessing the GI-ORIS platform to improve oral delivery of biologics. A separate collaboration with Replicate Bioscience targets self-replicating RNA therapies for metabolic diseases, with milestone payments potentially reaching $550 million. Meanwhile, €432 million is being ploughed into the company's Irish facility in Athlone, with completion expected by 2028 — a clear signal that management is thinking in decades, not quarters.

Those capacity investments are already visible elsewhere. A former Novavax plant in the Czech Republic has been repurposed to produce proteins for next-generation metabolic treatments. Fresh capital is flowing into the Tianjin site in China for injection device manufacturing. This is not a company retreating from the market; it is one building the infrastructure for volume dominance in a world where pricing pressure is the new normal.

The clinical pipeline carries both promise and nuance. Phase 3 data from the REIMAGINE studies show that CagriSema — a combination of semaglutide and a new amylin analogue — significantly reduces blood glucose and body weight. But the market had already priced in disappointment after earlier head-to-head comparisons failed to demonstrate non-inferiority against competing products on certain obesity metrics. That ambiguity leaves the stock in a technical no-man's-land: the RSI sits at 53, neither overbought nor oversold, and the share price is barely 3% above its 50-day moving average. The 30-day volatility of 28.56% underlines that the transition from growth-wonder to cash-rich pharma giant is far from smooth.

At a market capitalisation of roughly €168 billion, Novo Nordisk no longer carries the speculative tech-like premium that once inflated its valuation to unsustainable levels. The ransomware threat, the pipeline questions, and the competitive pressure from Eli Lilly all argue for caution. But the sheer scale of the oral Wegovy rollout — 3 million scripts out of the gate, a UK approval, and a China filing on the horizon — suggests that the story has not broken. It has simply become more complicated, more expensive, and more dependent on execution. For investors willing to hold through the volatility, the risk-reward calculus may be shifting in their favour.